Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 537-556

  Scher, Howard I ^a   Eisenberger, Mario ^b   D'Amico, Anthony V ^b   Halabi, Susan ^b   Small, Eric J ^b   Morris, Michael ^b   Kattan, Michael W ^b   Roach, Mack ^b   Kantoff, Philip ^b   Pienta, Kenneth J ^b   Carducci, Michael A ^b   Agus, David ^b   Slovin, Susan F ^b   Heller, Glenn ^b   Kelly, William Kevin ^b   Lange, Paul H ^b   Petrylak, Daniel ^b   Berg, William ^b   Higano, Celestra ^b   Wilding, George ^b   Moul, Judd W ^b   Partin, Alan N ^b   Logothetis, Christopher ^b   Soule, Howard R ^b   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DISEASE MARKER; EVALUATION; HUMAN; METASTASIS; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; ARTICLE; BLOOD; HEALTH CARE PLANNING; MALE; MORTALITY; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; PATHOLOGY; PROSTATE TUMOR; UNITED STATES;

CLINICAL TRIALS; ELIGIBILITY DETERMINATION; HEALTH PLANNING GUIDELINES; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; UNITED STATES;

EID: 1442290324     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.099     Document Type: Review

References (85)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
2. Svetec D, Thompson IM: PSA screening: Current controversy. Ann Oncol 9:1283-1288, 1998
3. Dixon SC, Knopf KB, Figg WD: The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 53:73-91, 2001
4. Denmeade SR, Sokoll LJ, Dalrymple S, et al: Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54:249-257, 2003
5. Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 163:1632-1642, 2000
6. Vollmer RT, Humphrey PA: Tumor volume in prostate cancer and serum prostate-specific antigen: Analysis from a kinetic viewpoint. Am J Clin Pathol 119:80-89, 2003
7. Pound CR, Partin AW, Eisenberger MA, et al: Natural history of progression to metastases an death from prostate cancer in men with PSA recurrence following radical prostatectomy. JAMA 281:1591-1597, 1999
8. Scher HI, Heller G: Clinical states in prostate cancer: Towards a dynamic model of disease progression. Urology 55:323-327, 2000
9. Fleming C, Wasson JH, Albertsen PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269:2650-2659, 1993
10. Kattan MW, Stapleton AMF, Wheeler TM, et al: Evaluation of a nomogram for predicting pathological stage of men with clinically localized prostate cancer. Cancer 79:528-537, 1997
11. Padula GD, Zelefsky MJ, Venkatraman ES, et al: Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 52:439-443, 2002
12. Gulley JL, Figg WD, Carter J, et al: A prospective analysis of the time to normalization of serum testosterone (T) following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial utilizing intermittent hormonal therapy. Proc Am Soc Clin Oncol 22:396, 2003 (abstr 1592)
13. Lukka H, Warde P, Pickles T, et al: Controversies in prostate cancer radiotherapy: Consensus development. Can J Urol 8:1314-1322, 2001
14. Taylor JM, Griffith KA, Sandler HM: Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50:1212-1219, 2001
15. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991
16. Han M, Partin AW, Zahurak M, et al: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517-523, 2003
17. Gretzer MB, Trock BJ, Han M, et al: A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol 168:1419-1422, 2002
18. Amling CL, Bergstralh EJ, Blute ML, et al: Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J Urol 165:1146-1151, 2001
19. Amling CL, Blute ML, Bergstralh EJ, et al: Defining biochemical progression after radical prostatectomy: What is appropriate PSA cut-point? J Urol 163:284, 2000 (suppl; abstr)
20. Panel ASTRO: Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041, 1997
21. Kattan MW, Zelefsky MJ, Kupelian PA, et al: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18:3352-3359, 2000
22. Critz FA, Levinson AK, Williams WH, et al: Prostate-specific antigen nadir: The optimal level after irradiation for prostate cancer. J Clin Oncol 14:2893-2900, 1996
23. Taplin ME: Biochemical (PSA) relapse in prostate cancer. PPO Updates 17:1-14, 2003
24. Critz FA, Williams WH, Benton JB, et al: Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163: 1085-1089, 2000
25. Hanlon AL, Pinover WH, Horwitz EM, et al: Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 50:845-849, 2001
26. Das P, Chen MH, Valentine K, et al: Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. Int J Radiat Oncol Biol Phys 54:698-702, 2002
27. Ballentine Carter H, Morrell CH, Pearson JD, et al: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostatic disease. Cancer Res 52:3323-3328, 1992
28. Patel A, Dorey F, Franklin J, et al: Recurrence patterns after radical retropubic prostatectomy: Clinical utility of PSA doubling times and log slope PSA (prostate specific antigen). J Urol 158:1441-1445, 1997
29. DiPaola RS, Zhang H, Lambert GH, et al: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339:785-791, 1998
30. Leventis AK, Shariat SF, Kattan MW, et al: Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19: 1030-1039, 2001
31. Laufer M, Pound CR, Carducci MA, et al: Management of patients with rising prostate-specific antigen after radical prostatectomy. Urology 55:309-315, 2000
32. Moul JW, Kane CJ, Malkowicz SB: The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am 28:459-472, 2001
33. Cher ML, Bianco FJ Jr, Lam JS, et al: Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160:1387-1391, 1998
34. Sella T, Schwartz LH, Swindle PW, et al: Endorectal coil MR in patients with suspected local recurrence following prostatectomy. Am J Radiol (in press)
35. Goldenberg SL, Carter M, Dashefsky S, et al: Sonographic characteristics of the urethrovesical anastomosis in the early post-radical prostatectomy patient. J Urol 147:1307-1309, 1992
36. Connolly JA, Shinohara K, Presti JC Jr, et al: Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47:225-231, 1996
37. Kao CH, Hsieh JF, Tsai SC, et al: Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases. Anticancer Res 20:2189-2192, 2000
38. Sartor O, McLeod D: Indium-111-capromab pendetide scans: An important test relevant to clinical decision making. Urology 57: 399-401, 2001
39. Hinkle GH, Burgers JK, Neal CE, et al: Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 83:739-747, 1998
40. Holmes EH: PSMA specific antibodies and their diagnostic and therapeutic use. Expert Opin Investig Drugs 10:511-519, 2001
41. Izawa JI, Madsen LT, Scott SM, et al: Salvage cryotherapy for recurrent prostate cancer after radiotherapy: Variables affecting patient outcome. J Clin Oncol 20:2664-2671, 2002
42. Beyer D: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 53:2-10, 1999
43. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491-500, 1998
44. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy of interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974, 1998
45. Moul JW, Connelly RR, Lubeck DP, et al: Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 166:1322-1327, 2001
46. Partin AW, Yoo J, Ballentine Carter H, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993
47. Roach M III: Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:1923-1924, 1993
48. Roach M III: You say either, I say either, but let's not call the whole thing off: Models for predicting the risk of lymph node involvement in patients with prostate cancer. Int J Radiat Oncol Biol Phys 34:749-751, 1996
49. Roach M, Lu J, Pilepich MV, et al: Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47:609-615, 2000
50. Vollmer RT, Humphrey PA: The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am J Clin Pathol 116:864-870, 2001
51. D'Amico AV, Moul J, Carroll PR, et al: Vital statistics following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. Proc Am Soc Clin Oncol 22:381, 2003 (abstr 1528)
52. Sandler HM, Pajak TF, Hanks GE, et al: Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Proc Am Soc Clin Oncol 22:381, 2003 (abstr 1529)
53. Katz MS, Zelefsky MJ, Venkatraman ES, et al: Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21:483-489, 2003
54. Stephenson AJ, Shariat SF, Kattan MW, et al: Predicting the outcome of salvage radiotherapy for suspected local recurrence of prostate cancer after radical prostatectomy. Proc Am Soc Clin Oncol 22:392, 2003 (abstr 1577)
55. Eisenberger MA, Partin AW, Pound C, et al: Natural history of progression of patients with biochemical (PSA) relapse following radical prostatectomy: Update. Proc Am Soc Clin Oncol 22:380, 2003 (abstr 1527)
56. Roberts SG, Blute ML, Bergstralh EJ, et al: PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76:576-581, 2001
57. Kwan WB, Pickles T, Paltiel C: Does PSA failure in prostate cancer patients necessarily increase the risk of prostate cancer related death: An analysis in a cohort of 1790 patients. Proc Am Soc Clin Oncol 22:380, 2003 (abstr 1526)
58. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-238, 1997
59. Zagars GK, Pollack A: Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44:213-221, 1997
60. Sandler HM, Dunn RL, McLaughlin W, et al: Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 48:629-633, 2000
61. D'Amico AV, Cote K, Loffredo M, et al: Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20:4567-4573, 2002
62. D'Amico AV, Moul JW, Carroll PR, et al: Vital statistics following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. Proc Am Soc Clin Oncol 39, 2003
63. D'Amico AV, Moul JW, Carroll PR, et al: Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Natl Cancer Inst 95:1376-1383, 2003
64. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol 17:3461-3467, 1999
65. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
66. Kelly WK, Scher HI, Mazumdar M, et al: Prostate specific antigen as a measure of disease outcome in hormone-refractory prostatic cancer. J Clin Oncol 11:607-615, 1993
67. Kelly WK, Osman I, Reuter VE, et al: The development of biologic end points in patients treated with differentiated agents: An experience of rentinoids in prostate cancer. Clin Cancer Res 6:838-846, 2000
68. Scher HI, Mazumdar M, Kelly WK: Clinical trials in relapsed prostate cancer: Defining the target. J Natl Cancer Inst 88:1623-1634, 1996
69. Saad R, Bukowski RM, Lipton A, et al: Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to prostate and renal cancer. Proc Am Soc Clin Oncol 22:379, 2003 (abstr 1523)
70. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
71. The Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer. N Engl J Med 319:677-683, 1988
72. Thalmann GN, Sikes RA Chang S-M, et al: Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88:794-801, 1996
73. Solit DB, Zheng FF, Drobnjak M, et al: 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8:986-993, 2002
74. Agus DB, Golde DW, Sgouros G, et al: Positron emission tomography of a human prostate cancer xenograft: The association of changes in deoxyglucose accumulation and response to hormonal therapy. Cancer Res 58: 3009-3014, 1998
75. Scher HI: HER2 in prostate cancer: A viable target or innocent bystander? J Natl Cancer Inst 92:1866-1868, 2000
76. Scher HI: Prostate cancer: Defining therapeutic objectives and improving overall outcomes. Cancer 97(suppl 3):758-771, 2003
77. Uehara H, Kim SJ, Karashima T, et al: Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 95:458-470, 2003
78. Singh D, Febbo PG, Ross K, et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1:203-209, 2002
79. Fazzari M, Heller G, Scher HI: The phase II/III transition (phase IIb): Toward the proof of efficacy in cancer clinical trials. Control Clin Trials 21:360-368, 2000
80. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997
81. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999
82. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997
83. See WA, Wirth MP, McLeod DG, et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: First analysis of the early prostate cancer program. J Urol 168:429-435, 2002
84. Verbel DA, Heller G, Kelly WK, et al: Quantifying the amount of variation in survival explained by PSA. Clin Cancer Res 8:2576-2579, 2002
85. Roth AJ, Kornblith AB, Batel-Copel L, et al: Rapid screening for psychological distress in men with prostate cancer: A pilot study. Cancer 82:1904-1908, 1998